<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The slow time course of <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>/reperfusion opened a realistic time window for the application of protective therapies to prevent spreading of brain damage </plain></SENT>
<SENT sid="1" pm="."><plain>In this work, we studied the ability of micromolar concentrations of this <z:chebi fb="5" ids="47916">flavonoid</z:chebi> in the blood to protect against brain damage induced by transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="2" pm="."><plain>Transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in adult rats and brain damage has been monitored by 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) staining, <z:chebi fb="1" ids="51686">hematoxylin</z:chebi>-eosin (H-E) staining, 'in situ' terminal deoxyribonucleotidyl transferase-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi>-<z:chebi fb="0" ids="31624">fluorescein</z:chebi> nick end labeling (TUNEL), 'in situ' metalloproteinase activity using DQ-gelatin and loss of anti-laminin staining </plain></SENT>
<SENT sid="3" pm="."><plain>Intravenous injections of <z:chebi fb="0" ids="28499">kaempferol</z:chebi>, at a dose of 10-15 mumol/L of blood 30 min before the induction of a 60 min <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-episode and just after reperfusion, led to &gt;90% and 70-80% (TTC, H-E, TUNEL) decrease of brain damage in the temporal-frontal areas of neocortex and striatum, respectively, but only 40-50% decrease of brain damage was observed in the hippocampus and vicinal caudal areas of the striatum </plain></SENT>
<SENT sid="4" pm="."><plain>This treatment with <z:chebi fb="0" ids="28499">kaempferol</z:chebi> also produced a similar reduction of metalloproteinase activation and loss of anti-laminin staining in cortical and striatum <z:mpath ids='MPATH_124'>infarct</z:mpath> areas </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="28499">Kaempferol</z:chebi> treatment efficiently protected against nitrosative-<z:mp ids='MP_0003674'>oxidative stress</z:mp> after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion, as shown by nearly complete protection against the increase of protein nitrotyrosines, and also afforded strong protection against the increase of apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> (TUNEL) and biochemical markers of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, such as caspase-9 activity and poly-(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase degradation </plain></SENT>
<SENT sid="6" pm="."><plain>On these grounds, a potential new therapeutic role of <z:chebi fb="0" ids="28499">kaempferol</z:chebi> to <z:hpo ids='HP_0011009'>acute</z:hpo> treatment of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> is suggested </plain></SENT>
</text></document>